Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus

Next Previous
X
Search
Trial Profile

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Corticosteroids; Corticosteroids; Cyclophosphamide; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms BELONG
  • Sponsors Genentech

    • Most Recent Events

    • 15 Nov 2023 Initial post hoc analysis of patients in the control arms of the LUNAR and BELONG trial presented at the ACR Convergence 2023
    • 01 Mar 2023 Results comparing differences between B-cell depletion in lupus nephritis patient populations who received rituximab (LUNAR), ocrelizumab (BELONG), or obinutuzumab (NOBILITY), published in the Clinical Immunology
    • 20 Dec 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top